Generally, all the treatments attenuated LPS-induced upregulation of those inflammatory markers without statistical significance, except for HCC + SH that reduced TLR-4, IL-6 and IL-23A, of about 3.8, 4 and 6-fold respectively compared to stimulated CTR (Figure 4c–e). This evidence concerns the gene IL6 and hepatocellular carcinoma.